Page last updated: 2024-12-05

tempol-h

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

TEMPOL-H: hydroxylamine (protonated, reduced) form of TEMPOL; a N-hydroxyl form of LASTAR A; TEMPOL is paramagnetic radical used in NMR as SPIN LABELS whereas TEMPOL-H is not [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-hydroxy-TEMPO : A member of the class of aminoxyls that is TEMPO carrying a hydroxy substituent at position 4. It is a radical scavenger which exhibits anti-inflammatory and analgesic properties. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5395
CHEMBL ID117649
SCHEMBL ID23902
MeSH IDM0491579

Synonyms (65)

Synonym
ot-674
tempol-h
ot 674
4-hydroxy-2,2,6,6-tetramethyl-1-hydroxypiperidine
unii-v55xb6it82
4-piperidinol, 1-hydroxy-2,2,6,6-tetramethyl-
tempol h
n-hydroxy-2,2,6,6-tetramethylpiperidine
v55xb6it82 ,
4-hydroxy-2,2,6,6-tetramethyl-n-hydroxypiperidine
1-hydroxy-2,2,6,6-tetramethyl-4-piperidinol
4-piperidinol, 2,2,6,6-tetramethyl-, 1-oxide
4-hydroxy-1-oxyl-2,2,6,6-tetramethylpiperidine
2,6,6-tetramethyl-4-piperidinol 1-oxide
nsc142784
4-hydroxy-2,6,6-tetramethylpiperidinooxy radical
4-hydroxy-2,6,6-tetramethylpiperidinooxy
4-hydroxy-2,6,6-tetramethylpiperidine n-oxide
2,6,6-tetramethyl-4-hydroxypiperidine 1-oxide
2,6,6-tetramethyl-4-hydroxypiperidinooxy radical
4-hydroxy-tempo
NCI60_000934
CHEMBL117649
3637-10-3
FT-0691316
1-hydroxy-2,2,6,6-tetramethylpiperidin-4-ol
STK246905
2,2,6,6-tetramethylpiperidine-1,4-diol
A816073
AKOS006228301
SCHEMBL23902
4h-tempo
4-hydroxy-2,2,6,6-tetramethylpiperidin-n-oxyl
ho-tempo
4-hydroxy-2,2,6,6-tetramethyl-piperdine-n-oxyl
4-hydroxy-2,2,6,6-tetramethylpiperidine n-oxyl
4-hydroxy tempo
1-oxyl-4-hydroxy-2,2,6,6-tetramethylpiperidine
1,4-dihydroxy-2,2,6,6-tetramethylpiperidine
1,4-dihydroxy-2,2,6,6-tetramethyl-piperidine
4hydroxy-1-oxyl-2,2,6,6-tetramethylpiperidine
1-oxyl-2,2,6,6-tetramethyl-4-hydroxypiperidine
1-oxyl-2,2,6,6-tetramethylpiperidin-4-ol
1-hydroxy-2,2,6,6-tetramethyl-4-hydroxypiperidine
4-hydroxyl-1-oxyl-2,2,6,6-tetramethylpiperidine
1-oxyl-2,2,6,6-tetramethyl4-hydroxypiperidine
J-200070
J-660069
HMS3651B10
4-hydroxy-2,2,6,6-tetramethyl piperidinoxyl
4-hydroxy-2,2,6,6-tetramethyl-1-piperidin-1-yloxy, free radical
SY002737
SW219557-1
Q4637150
PS-15551
tempol (4-hydroxy-tempo)
[o]n1c(c)(c)cc(o)cc1(c)c
D71066
Q27291546
2,2,6,6-tetramethyl-piperidine-1,4-diol
1-hydroxy-2,2,6,6-tetramethyl-piperidin-4-ol
PB47762
E83391
DTXSID40859711
PD062105
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID216900Mean surviving fraction of V79 cells following a 12-Gy dose of radiation.1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Studies of structure-activity relationship of nitroxide free radicals and their precursors as modifiers against oxidative damage.
AID216891Mean surviving fraction of V79 cells following a 1-h exposure to H2O21998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Studies of structure-activity relationship of nitroxide free radicals and their precursors as modifiers against oxidative damage.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (3.70)18.2507
2000's7 (25.93)29.6817
2010's16 (59.26)24.3611
2020's3 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.05 (24.57)
Research Supply Index3.40 (2.92)
Research Growth Index5.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Open Label Study to Assess the Safety and Clinical Efficacy of MBM-02 to Increase Survival in Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) [NCT04874506]Phase 255 participants (Anticipated)Interventional2021-06-01Not yet recruiting
A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer [NCT04337099]0 participants Expanded AccessAvailable
An Open Label, Dose Comparison Study to Assess the Efficacy of MBM-02 (Tempol) as a Treatment for Patients Diagnosed With Prostate Cancer in Biochemical Recurrence [NCT04876755]Phase 255 participants (Anticipated)Interventional2021-05-30Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]